Linked Life Data

1967920

Source:http://linkedlifedata.com/resource/pubmed/id/1967920

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2 Pt 2
pubmed:dateCreated
1990-3-14
pubmed:abstractText
In a double-blind study, 29 patients suffering from pollen asthma were administered placebo for 14 days and were compared with 28 patients administered cetirizine, a new drug displaying a potent and selective H1 antagonism and inhibiting effect on infiltrating cells. FEV1 and FVC were measured before and after treatment. A subjective self-assessment by the patients included daily ENT and pulmonary scores, and beta 2 consumption. The peak flow was also measured every day as well as the rescue drug administration. In the placebo group, the FEV1, FVC, and peak flow values decreased significantly and the ENT and pulmonary scores became worse. Most of the patients in this group dropped out despite the high use of fenoterol and terfenadine. In the cetirizine group, FEV1, FVC, and peak flow values remained close to the predicted values; the ENT and pulmonary scores improved significantly despite low beta 2 consumption. The number of dropouts was low and the administration of corticosteroids was exceptionally limited.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0003-4738
pubmed:author
pubmed:issnType
Print
pubmed:volume
64
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
224-8
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1990
pubmed:articleTitle
Protective effect of cetirizine in patients suffering from pollen asthma.
pubmed:affiliation
UCB Pharmaceutical Sector, International Development Chemin du Foriest, Belgium.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial